Progress in SPECT/CT Imaging of Prostate Cancer
暂无分享,去创建一个
Kenneth H. Wong | Youngho Seo | Bruce H Hasegawa | Kenneth H Wong | B. Hasegawa | Youngho Seo | R. Hawkins | B. Franc | Benjamin L Franc | Randall A Hawkins
[1] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[2] A.J. Da Silva,et al. Absolute quantitation of myocardial activity in phantoms , 1998, 1998 IEEE Nuclear Science Symposium Conference Record. 1998 IEEE Nuclear Science Symposium and Medical Imaging Conference (Cat. No.98CH36255).
[3] Mingshan Sun,et al. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] T. Turkington,et al. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. , 2005, AJR. American journal of roentgenology.
[5] C. J. Schettino,et al. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. , 2004, AJR. American journal of roentgenology.
[6] S. Vallabhajosula,et al. Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer , 2005 .
[7] M. Manyak,et al. (111) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY , 1998 .
[8] A W Partin,et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.
[9] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[10] N. Bander. Technology Insight: monoclonal antibody imaging of prostate cancer , 2006, Nature Clinical Practice Urology.
[11] M. Roach,et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. , 1998, International journal of radiation oncology, biology, physics.
[12] Sam S. Chang,et al. The clinical role of prostate-specific membrane antigen (PSMA). , 2002, Urologic oncology.
[13] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] Bruce H. Hasegawa,et al. Absolute quantitation of myocardial activity in phantoms , 1998 .
[15] Kenneth H. Wong,et al. Calculation and validation of the use of effective attenuation coefficient for attenuation correction in In-111 SPECT. , 2005, Medical physics.
[16] Shankar Vallabhajosula,et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Renshaw,et al. Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer. , 2002, Urology.
[18] T. Polascik,et al. Capromab Pendetide imaging of prostate cancer. , 2000, Cancer biotherapy & radiopharmaceuticals.
[19] N. Bander,et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.